NASDAQ:MGTX MeiraGTx Q3 2023 Earnings Report $7.69 -0.03 (-0.39%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$7.79 +0.10 (+1.30%) As of 09/5/2025 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast MeiraGTx EPS ResultsActual EPS-$0.74Consensus EPS -$0.63Beat/MissMissed by -$0.11One Year Ago EPSN/AMeiraGTx Revenue ResultsActual Revenue$5.10 millionExpected Revenue$3.54 millionBeat/MissBeat by +$1.56 millionYoY Revenue GrowthN/AMeiraGTx Announcement DetailsQuarterQ3 2023Date11/14/2023TimeN/AConference Call DateTuesday, November 14, 2023Conference Call Time7:00AM ETUpcoming EarningsMeiraGTx's Q3 2025 earnings is scheduled for Wednesday, November 12, 2025, with a conference call scheduled on Friday, November 14, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) MeiraGTx Earnings HeadlinesMeiraGTx Holdings PLC Reports Q2 2025 Earnings: EPS of -$0. ...August 16, 2025 | gurufocus.comMeiraGTx Reports Progress in Genetic Medicines DevelopmentAugust 15, 2025 | msn.com+2,400% return last time this happenedPorter Stansberry has built his reputation on bold predictions that challenge the mainstream — from the 2007 financial crisis to the dollar’s ongoing decline. Now, he and his top analyst say they’ve uncovered what could be the “next MicroStrategy” moment. Back in 2020, MicroStrategy quietly pivoted into Bitcoin, and the result was a 2,400% gain for investors in just over five years. Today, Porter believes a little-known financial services firm could be set up for a similar asymmetric move — one with multiple catalysts converging in the months ahead.September 6 at 2:00 AM | Porter & Company (Ad)MeiraGTx reports Q2 EPS (48c) vs (76c) last yearAugust 14, 2025 | msn.comMeiraGTx Reports Second Quarter 2025 Financial and Operational ResultsAugust 14, 2025 | globenewswire.comMeiraGTx Holdings plc's (NASDAQ:MGTX) large institutional owners must be happy as stock continues to impress, up 25% over the past weekJuly 9, 2025 | finance.yahoo.comSee More MeiraGTx Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like MeiraGTx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MeiraGTx and other key companies, straight to your email. Email Address About MeiraGTxMeiraGTx (NASDAQ:MGTX) is a clinical-stage biotechnology company dedicated to developing gene therapies for the treatment of rare diseases. Founded in 2014 as an outgrowth of research at University College London, the company focuses on leveraging adeno-associated virus (AAV) vectors to deliver functional genes to target tissues. MeiraGTx’s pipeline spans ocular, central nervous system and systemic indications, addressing conditions such as inherited retinal dystrophies and neurodegenerative disorders that currently lack effective therapies. The company’s lead programs include AAV-based candidates designed to restore or replace defective genes underlying rare retinal diseases and to modulate cellular pathways in neurological disorders. MeiraGTx has established an end-to-end platform encompassing vector design, process development, and manufacturing scale-up, with capabilities housed in facilities across the United Kingdom and the United States. This integrated approach aims to accelerate the transition from preclinical research to clinical trials and, ultimately, patient access. MeiraGTx completed its initial public offering on the Nasdaq in April 2018 and operates research laboratories in London alongside a manufacturing and clinical operations center in the New York metropolitan area. The company’s leadership team comprises industry veterans with extensive experience in gene therapy development, regulatory affairs and commercialization. MeiraGTx continues to advance its clinical programs in collaboration with academic institutions and contract research organizations, targeting global patient populations in need of novel therapeutic options.Written by Jeffrey Neal JohnsonView MeiraGTx ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why DocuSign Could Be a SaaS Value Play After Q2 EarningsAffirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a WinnerWhat to Watch for From D-Wave Now That Earnings Are DoneDICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy?NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Upcoming Earnings Synopsys (9/9/2025)Oracle (9/9/2025)Adobe (9/11/2025)FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
